Dekorationsartikel gehören nicht zum Leistungsumfang.
Sprache:
Englisch
112,95 €*
Versandkostenfrei per Post / DHL
Lieferzeit 2-3 Wochen
Kategorien:
Beschreibung
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems.
More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds.
Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds.
Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems.
More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds.
Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds.
Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
Über den Autor
Michael Winkelman, PhD, is retired from the School of Human Evolution and Social Change at Arizona State University, where he served as director of the medical anthropology program.
Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.
Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.
Zusammenfassung
Provides timely information for clinicians, researchers, and advanced students of psychology, medicine, and public health, from leading clinicians, researchers, and administrators in the field
Inhaltsverzeichnis
AcknowledgmentsChapter 1 Introduction: The Psychedelic Renaissance Continues
Michael Winkelman and Ben SessaPart One PsychiatryChapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary BravoChapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben SessaChapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH RuckerChapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc EttensohnChapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de AraújoPart Two Substance AbuseChapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg LydallChapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime HallakChapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh AthertonPart Three Medical HypothesesChapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila SzaboChapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila SzaboChapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita KocárováPart Four Treatment and TrainingChapter 13 Guidelines in Applying Psychedelic Therapies
Friederike MeckelChapter 14 Training Psychedelic Therapists
Janis PhelpsPart Five Societal Engagement with PsychedelicsChapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel LiraChapter 16 Microdosing Psychedelics
James Fadiman and Sophia KorbChapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick DoblinAbout the Editors and ContributorsIndex
Michael Winkelman and Ben SessaPart One PsychiatryChapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary BravoChapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben SessaChapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH RuckerChapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc EttensohnChapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de AraújoPart Two Substance AbuseChapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg LydallChapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime HallakChapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh AthertonPart Three Medical HypothesesChapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila SzaboChapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila SzaboChapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita KocárováPart Four Treatment and TrainingChapter 13 Guidelines in Applying Psychedelic Therapies
Friederike MeckelChapter 14 Training Psychedelic Therapists
Janis PhelpsPart Five Societal Engagement with PsychedelicsChapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel LiraChapter 16 Microdosing Psychedelics
James Fadiman and Sophia KorbChapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick DoblinAbout the Editors and ContributorsIndex
Details
| Erscheinungsjahr: | 2019 |
|---|---|
| Produktart: | Ratgeber |
| Rubrik: | Gesundheit |
| Thema: | Lexika |
| Medium: | Buch |
| Seiten: | 400 |
| ISBN-13: | 9781440864100 |
| ISBN-10: | 1440864101 |
| Sprache: | Englisch |
| Ausstattung / Beilage: | HC gerader Rücken kaschiert |
| Einband: | Gebunden |
| Redaktion: | Winkelman, Michael |
| Hersteller: | Bloomsbury 3PL |
| Maße: | 240 x 161 x 26 mm |
| Von/Mit: | Michael Winkelman |
| Erscheinungsdatum: | 31.03.2019 |
| Gewicht: | 0,765 kg |
Über den Autor
Michael Winkelman, PhD, is retired from the School of Human Evolution and Social Change at Arizona State University, where he served as director of the medical anthropology program.
Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.
Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.
Zusammenfassung
Provides timely information for clinicians, researchers, and advanced students of psychology, medicine, and public health, from leading clinicians, researchers, and administrators in the field
Inhaltsverzeichnis
AcknowledgmentsChapter 1 Introduction: The Psychedelic Renaissance Continues
Michael Winkelman and Ben SessaPart One PsychiatryChapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary BravoChapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben SessaChapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH RuckerChapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc EttensohnChapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de AraújoPart Two Substance AbuseChapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg LydallChapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime HallakChapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh AthertonPart Three Medical HypothesesChapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila SzaboChapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila SzaboChapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita KocárováPart Four Treatment and TrainingChapter 13 Guidelines in Applying Psychedelic Therapies
Friederike MeckelChapter 14 Training Psychedelic Therapists
Janis PhelpsPart Five Societal Engagement with PsychedelicsChapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel LiraChapter 16 Microdosing Psychedelics
James Fadiman and Sophia KorbChapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick DoblinAbout the Editors and ContributorsIndex
Michael Winkelman and Ben SessaPart One PsychiatryChapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary BravoChapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben SessaChapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH RuckerChapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc EttensohnChapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de AraújoPart Two Substance AbuseChapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg LydallChapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime HallakChapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh AthertonPart Three Medical HypothesesChapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila SzaboChapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila SzaboChapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita KocárováPart Four Treatment and TrainingChapter 13 Guidelines in Applying Psychedelic Therapies
Friederike MeckelChapter 14 Training Psychedelic Therapists
Janis PhelpsPart Five Societal Engagement with PsychedelicsChapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel LiraChapter 16 Microdosing Psychedelics
James Fadiman and Sophia KorbChapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick DoblinAbout the Editors and ContributorsIndex
Details
| Erscheinungsjahr: | 2019 |
|---|---|
| Produktart: | Ratgeber |
| Rubrik: | Gesundheit |
| Thema: | Lexika |
| Medium: | Buch |
| Seiten: | 400 |
| ISBN-13: | 9781440864100 |
| ISBN-10: | 1440864101 |
| Sprache: | Englisch |
| Ausstattung / Beilage: | HC gerader Rücken kaschiert |
| Einband: | Gebunden |
| Redaktion: | Winkelman, Michael |
| Hersteller: | Bloomsbury 3PL |
| Maße: | 240 x 161 x 26 mm |
| Von/Mit: | Michael Winkelman |
| Erscheinungsdatum: | 31.03.2019 |
| Gewicht: | 0,765 kg |
Warnhinweis
Ähnliche Produkte
Taschenbuch
Lieferzeit 1-2 Wochen
Taschenbuch
Lieferzeit 4-7 Werktage
Taschenbuch
Aktuell nicht verfügbar
Taschenbuch
Lieferzeit 1-2 Wochen
Taschenbuch
Lieferzeit 4-7 Werktage
Buch
Lieferzeit 1-2 Wochen
Taschenbuch
Taschenbuch
